Citadel Advisors’s AgomAb Therapeutics NV AGMB Stock Holding History

Citadel Advisors’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,000	Closed	-$367K	–	15432
2026 Q1	$367K	Buy	+35,000	New	+$496K	﹤0.01%	10009

Other funds holding AGMB

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's AGMB Position: Q2 2026 in Review

Citadel Advisors sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 35,000 shares — an estimated $367K sold.

Citadel Advisors first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $367K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

Citadel Advisors reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 35,000 AgomAb Therapeutics NV shares in Q2 2026, an estimated $367K.
Citadel Advisors first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
Citadel Advisors's AgomAb Therapeutics NV position peaked at $367K in Q1 2026.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.